THAP1 Mutation Detection Using Segmented Primers for DYT6 Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and diagnosis of dystonia associated with THAP1 gene mutations, and there is a need for therapies to treat this condition.
Innovation Solution
The development of isolated THAP1 nucleic acids and peptides, including those with specific mutations, along with expression constructs and methods for detecting THAP1 mutations in biological samples, as well as therapies such as gene therapeutics and protein/antibody-based treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current general dystonia detection methods are used, then diagnosis can be performed, but detection precision for THAP1-specific mutations is insufficient
Solution Approach 1:
The patent segments the dystonia diagnosis process into specific THAP1 gene mutation detection components. It divides the detection into targeting specific exons (exons 1-4) and specific mutation types (nucleotide substitutions, deletions, insertions) within the THAP1 gene, allowing precise detection of DYT6 dystonia mutations while maintaining a manageable diagnostic workflow through focused genetic analysis
2Reliability
If no specific THAP1 detection methods are available, then general dystonia screening can be performed, but accurate diagnosis of DYT6 dystonia cannot be achieved
Solution Approach 1:
The patent employs molecular biology intermediaries including specific primers, probes, and PCR reagents designed to target THAP1 gene sequences. These intermediaries enable reliable detection of DYT6 mutations by mediating between the genetic material and detection instruments, allowing accurate diagnosis through standardized molecular genetics techniques that are widely accessible in clinical laboratories
3Adaptability or versatility
If comprehensive dystonia therapies are used, then multiple symptoms can be addressed, but specific treatment for THAP1-related dystonia is not available
Solution Approach 1:
The patent applies local quality by developing therapies specifically targeted at THAP1 gene dysfunction. This includes gene replacement strategies that deliver functional THAP1 copies, antisense oligonucleotides that target specific mutant transcripts, and small molecules that correct THAP1 folding or function. These localized interventions address the root cause of DYT6 dystonia while potentially maintaining broader symptom management capabilities
Data Source
AI summary
The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein/antibody based therapeutics.